Evaluation of target attainment of oral posaconazole suspension in immunocompromised children
Evaluation of target attainment of oral posaconazole suspension in immunocompromised children
复制标题
DOI：
10.1093/jac/dkz481
复制
发表时间：
2020-03-01
影响因子：
5.2
通讯作者：
Roberts, Jason A.
中科院分区：
文献类型：
--
作者：
Lai, Tony;Alffenaar, Jan-Willem;Roberts, Jason A.
背景：泊沙康唑是一种广谱抗真菌药，未获准用于儿童 = 700ng/mL 免疫功能低下儿童 = 7 天。记录泊沙康唑血浆浓度和突破性感染率。结果：共纳入70名患者，中位年龄为5岁（范围为3个月至12岁）。泊沙康唑平均血浆浓度为 783.4ng/mL (IQR 428.3-980ng/mL)，泊沙康唑血浆浓度≥700ng/mL 的患者比例为 47.9%。与未同时服用这些药物/粘膜炎/肠内喂养的患者相比，使用质子泵抑制剂、组胺 H-2 拮抗剂或胃复安、患有粘膜炎或肠内喂养的患者泊沙康唑血浆浓度较低（542.3 与 1069.8ng/mL；P
Background: Posaconazole is a broad-spectrum antifungal that is not licensed for use in children = 700ng/mL in immunocompromised children = 7days. Posaconazole plasma concentrations and rate of breakthrough infection were recorded.Results: A total of 70 patients were included with a median age of 5years (range 3months to 12years). The mean posaconazole plasma concentration was 783.4ng/mL (IQR 428.3-980ng/mL) and the percentage of patients with a posaconazole plasma concentration >= 700ng/mL was 47.9%. Patients who were on a proton pump inhibitor, a histamine H-2 antagonist or metoclopramide, had mucositis or were enterally fed had a lower posaconazole plasma concentration compared with patients without these co-administered drugs/mucositis/enteral feeding (542.3 versus 1069.8ng/mL; P